Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypomethylation and multiple sclerosis, the susceptibility factor?].

C J Cara Terribas1, L González Guijarro

  • 1Celltech Pharma España, Departamento Científico, Madrid, Spain. carlos.cara@celltechgroup.com

Neurologia (Barcelona, Spain)
|April 3, 2002
PubMed
Summary

Thiopurine methyltransferase (TPMT) activity is significantly lower in multiple sclerosis (MS) patients compared to other autoimmune diseases and healthy donors. This finding may indicate a role for defective methylation in MS susceptibility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Commentary on the letter: "Azathioprine and cavum carcinoma in a male patient with autoimmune hepatitis and Crohn's disease"].

Gastroenterologia y hepatologia·2001
Same author

Characterization of somatostatin binding sites in cytosolic fraction of rat intestinal mucosa.

Biochimica et biophysica acta·1984
See all related articles

Area of Science:

  • Pharmacogenomics
  • Neuroimmunology
  • Clinical Chemistry

Background:

  • Azathioprine, an immunosuppressant, is approved for relapsing-remitting multiple sclerosis (MS) in Spain.
  • Its efficacy relies on conversion to 6-thioguanine, mediated by thiopurine methyltransferase (TPMT).
  • Genetic variations in TPMT influence drug metabolism and patient outcomes.

Purpose of the Study:

  • To compare TPMT activity distributions across different patient groups and healthy donors.
  • To investigate the potential role of TPMT activity in MS susceptibility.

Main Methods:

  • TPMT activity was measured in red blood cells from 3,640 individuals in Spain.
  • Included patients with Crohn's disease, ulcerative colitis, MS, other autoimmune diseases, and healthy blood donors.

Related Experiment Videos

  • Statistical analysis compared mean TPMT activity between groups.

    • Main Results:

    • Mean TPMT activity in MS patients (17.1 ± 6.1 U/ml) was significantly lower (p < 0.001) than in Crohn's disease (20.0 ± 5.8 U/ml), ulcerative colitis (19.7 ± 6.1 U/ml), and donor groups (19.9 ± 6.3 U/ml).

    Conclusions:

    • Lower TPMT activity in MS patients suggests a potential link between impaired methylation and MS susceptibility.
    • Defective methylation profiles and hyperhomocysteinemia may contribute to MS pathogenesis.
    • This highlights the importance of TPMT phenotyping in managing patients with autoimmune diseases.